[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
[HTML][HTML] Imaging biomarkers in neurodegeneration: current and future practices
PNE Young, M Estarellas, E Coomans… - Alzheimer's research & …, 2020 - Springer
There is an increasing role for biological markers (biomarkers) in the understanding and
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
S Salloway, M Farlow, E McDade, DB Clifford… - Nature medicine, 2021 - nature.com
Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …
decades before the onset of clinical symptoms, enabling testing of interventions in the …
Gut microbiome composition may be an indicator of preclinical Alzheimer's disease
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
SE Schindler, JG Bollinger, V Ovod, KG Mawuenyega… - Neurology, 2019 - AAN Enterprises
Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …
OASIS-3: longitudinal neuroimaging, clinical, and cognitive dataset for normal aging and Alzheimer disease
PJ LaMontagne, TLS Benzinger, JC Morris, S Keefe… - medrxiv, 2019 - medrxiv.org
ABSTRACT OASIS-3 is a compilation of MRI and PET imaging and related clinical data for
1098 participants who were collected across several ongoing studies in the Washington …
1098 participants who were collected across several ongoing studies in the Washington …
Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light
Background and Objectives To evaluate whether plasma biomarkers of amyloid
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …
[HTML][HTML] CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease
Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ) 42/Aβ40 and the concentration of tau
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …
Assessment of racial disparities in biomarkers for Alzheimer disease
JC Morris, SE Schindler, LM McCue, KL Moulder… - JAMA …, 2019 - jamanetwork.com
Importance Racial differences in molecular biomarkers for Alzheimer disease may suggest
race-dependent biological mechanisms. Objective To ascertain whether there are racial …
race-dependent biological mechanisms. Objective To ascertain whether there are racial …
[HTML][HTML] Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)
Abstract The Dominantly Inherited Alzheimer Network (DIAN) is an international
collaboration studying autosomal dominant Alzheimer disease (ADAD). ADAD arises from …
collaboration studying autosomal dominant Alzheimer disease (ADAD). ADAD arises from …